PMC:7127067 / 15458-17789
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T47 | 359-362 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
T48 | 1704-1707 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T131 | 37-45 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T132 | 46-55 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T133 | 206-214 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T134 | 215-224 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T135 | 404-419 | Disease | denotes | virus infection | http://purl.obolibrary.org/obo/MONDO_0005108 |
T136 | 410-419 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T137 | 908-927 | Disease | denotes | 2019-nCoV infection | http://purl.obolibrary.org/obo/MONDO_0100096 |
T138 | 918-927 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T139 | 1083-1091 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T140 | 1092-1101 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T141 | 1312-1321 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T142 | 1322-1338 | Disease | denotes | virus infections | http://purl.obolibrary.org/obo/MONDO_0005108 |
T143 | 1420-1428 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T144 | 1429-1438 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T145 | 1615-1623 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T146 | 1624-1633 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T147 | 1843-1851 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T148 | 1852-1862 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
T149 | 1926-1934 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T150 | 2152-2160 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T151 | 2161-2170 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T129 | 112-113 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T130 | 250-256 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humans |
T131 | 404-409 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T132 | 626-627 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T133 | 982-987 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T134 | 1002-1003 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T135 | 1103-1105 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
T136 | 1131-1132 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T137 | 1245-1248 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T138 | 1322-1327 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T139 | 1689-1696 | http://purl.obolibrary.org/obo/PR_000018263 | denotes | peptide |
T140 | 1976-1982 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
T141 | 2043-2049 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humans |
T142 | 2118-2119 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T143 | 2129-2136 | http://purl.obolibrary.org/obo/NCBITaxon_9443 | denotes | primate |
T144 | 2226-2233 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T145 | 2281-2282 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T146 | 2307-2312 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T15 | 171-186 | Chemical | denotes | antiviral drugs | http://purl.obolibrary.org/obo/CHEBI_36044 |
T16 | 171-180 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T17 | 181-186 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T18 | 308-323 | Chemical | denotes | antiviral drugs | http://purl.obolibrary.org/obo/CHEBI_36044 |
T19 | 308-317 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T20 | 318-323 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T21 | 329-339 | Chemical | denotes | Nucleoside | http://purl.obolibrary.org/obo/CHEBI_33838 |
T22 | 359-382 | Chemical | denotes | HIV-protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_35660 |
T23 | 363-382 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
T25 | 372-382 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T26 | 439-448 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T27 | 570-585 | Chemical | denotes | antiviral drugs | http://purl.obolibrary.org/obo/CHEBI_36044 |
T28 | 570-579 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T29 | 580-585 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T30 | 661-672 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T31 | 681-690 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T32 | 699-708 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T33 | 754-765 | Chemical | denotes | ganciclovir | http://purl.obolibrary.org/obo/CHEBI_465284 |
T34 | 832-841 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T35 | 842-852 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T36 | 857-868 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T37 | 944-953 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T38 | 1377-1381 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T39 | 1564-1574 | Chemical | denotes | antivirals | http://purl.obolibrary.org/obo/CHEBI_22587 |
T40 | 1588-1592 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T41 | 1642-1651 | Chemical | denotes | Lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T42 | 1663-1687 | Chemical | denotes | Neuraminidase inhibitors | http://purl.obolibrary.org/obo/CHEBI_52425 |
T43 | 1677-1687 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T44 | 1689-1696 | Chemical | denotes | peptide | http://purl.obolibrary.org/obo/CHEBI_16670 |
T45 | 1718-1728 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T46 | 1824-1829 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T11 | 1704-1717 | http://purl.obolibrary.org/obo/GO_0032774 | denotes | RNA synthesis |
T12 | 1708-1717 | http://purl.obolibrary.org/obo/GO_0009058 | denotes | synthesis |
T13 | 2307-2330 | http://purl.obolibrary.org/obo/GO_0019048 | denotes | virus-host interactions |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T110 | 0-136 | Sentence | denotes | The person-to-person transmission of COVID-19 infection led to the isolation of patients that were administered a variety of treatments. |
T111 | 137-257 | Sentence | denotes | At present, there are no specific antiviral drugs or vaccine against COVID-19 infection for potential therapy of humans. |
T112 | 258-471 | Sentence | denotes | The only option available is using broad-spectrum antiviral drugs like Nucleoside analogues and also HIV-protease inhibitors that could attenuate virus infection until the specific antiviral becomes available [7]. |
T113 | 472-586 | Sentence | denotes | The treatment that have so far been attempted showed that 75 patients were administrated existing antiviral drugs. |
T114 | 587-785 | Sentence | denotes | The course of treatment included twice a day oral administration of 75 mg oseltamivir, 500 mg lopinavir, 500 mg ritonavir and the intravenous administration of 0·25 g ganciclovir for 3–14 days [26]. |
T115 | 786-937 | Sentence | denotes | Another report showed that the broad-spectrum antiviral remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro. |
T116 | 938-1024 | Sentence | denotes | These antiviral compounds have been used in human patients with a safety track record. |
T117 | 1025-1107 | Sentence | denotes | Thus, these therapeutic agents can be considered to treat COVID-19 infection [27]. |
T118 | 1108-1183 | Sentence | denotes | Furthermore, there are a number of other compounds that are in development. |
T119 | 1184-1444 | Sentence | denotes | These include the clinical candidate EIDD-2801 compound that has shown high therapeutic potential aganist seasonal and pandemic influenza virus infections and this represents another potential drug to be considered for the treatment of COVID-19 infection [28]. |
T120 | 1445-1729 | Sentence | denotes | Along those lines, until more specific therapeutics become available, it is reasonable to consider more broad-spectrum antivirals that provide drug treatment options for COVID-19 infection include Lopinavir/Ritonavir, Neuraminidase inhibitors, peptide (EK1), RNA synthesis inhibitors. |
T121 | 1730-1863 | Sentence | denotes | It is clear however, that more research is urgently needed to identify novel chemotherapeutic drugs for treating COVID-19 infections. |
T122 | 1864-2050 | Sentence | denotes | In order to develop pre-and post-exposure prophylaxis against COVID-19, there is an urgent need to establish an animal model to replicate the severe disease currently observed in humans. |
T123 | 2051-2331 | Sentence | denotes | Several groups of scientists are currently working hard to develop a nonhuman primate model to study COVID-19 infection to establish fast track novel therapeutics and for the testing of potential vaccines in addition to providing a better understanding of virus-host interactions. |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32113704-32007143-55638578 | 781-783 | 32007143 | denotes | 26 |
32113704-32007143-55638578 | 781-783 | 32007143 | denotes | 26 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
572 | 1663-1676 | Gene | denotes | Neuraminidase | Gene:4758 |
573 | 80-88 | Species | denotes | patients | Tax:9606 |
574 | 250-256 | Species | denotes | humans | Tax:9606 |
575 | 533-541 | Species | denotes | patients | Tax:9606 |
576 | 982-987 | Species | denotes | human | Tax:9606 |
577 | 988-996 | Species | denotes | patients | Tax:9606 |
578 | 2043-2049 | Species | denotes | humans | Tax:9606 |
579 | 329-339 | Chemical | denotes | Nucleoside | MESH:D009705 |
580 | 661-672 | Chemical | denotes | oseltamivir | MESH:D053139 |
581 | 681-690 | Chemical | denotes | lopinavir | MESH:D061466 |
582 | 699-708 | Chemical | denotes | ritonavir | MESH:D019438 |
583 | 754-765 | Chemical | denotes | ganciclovir | MESH:D015774 |
584 | 842-852 | Chemical | denotes | remdesivir | MESH:C000606551 |
585 | 857-868 | Chemical | denotes | chloroquine | MESH:D002738 |
586 | 1642-1661 | Chemical | denotes | Lopinavir/Ritonavir | MESH:C558899 |
587 | 37-45 | Disease | denotes | COVID-19 | MESH:C000657245 |
588 | 46-55 | Disease | denotes | infection | MESH:D007239 |
589 | 206-214 | Disease | denotes | COVID-19 | MESH:C000657245 |
590 | 215-224 | Disease | denotes | infection | MESH:D007239 |
591 | 410-419 | Disease | denotes | infection | MESH:D007239 |
592 | 908-927 | Disease | denotes | 2019-nCoV infection | MESH:C000657245 |
593 | 1083-1091 | Disease | denotes | COVID-19 | MESH:C000657245 |
594 | 1092-1101 | Disease | denotes | infection | MESH:D007239 |
595 | 1322-1338 | Disease | denotes | virus infections | MESH:D001102 |
596 | 1420-1428 | Disease | denotes | COVID-19 | MESH:C000657245 |
597 | 1429-1438 | Disease | denotes | infection | MESH:D007239 |
598 | 1615-1623 | Disease | denotes | COVID-19 | MESH:C000657245 |
599 | 1624-1633 | Disease | denotes | infection | MESH:D007239 |
600 | 1843-1851 | Disease | denotes | COVID-19 | MESH:C000657245 |
601 | 1852-1862 | Disease | denotes | infections | MESH:D007239 |
602 | 1926-1934 | Disease | denotes | COVID-19 | MESH:C000657245 |
603 | 2006-2020 | Disease | denotes | severe disease | MESH:D045169 |
604 | 2152-2160 | Disease | denotes | COVID-19 | MESH:C000657245 |
605 | 2161-2170 | Disease | denotes | infection | MESH:D007239 |